Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human metapneumovirus (hMPV) is a significant viral pathogen responsible for a high burden of respiratory disease, particularly in pediatric and geriatric populations (Van den Hoogen et al., 2001). A defining characteristic of hMPV, which distinguishes it from many other paramyxoviruses, is that it does not possess a hemagglutinin-neuraminidase (HN) protein (ViralZone, SIB). The viral surface is instead characterized by the Fusion (F) protein, the Attachment (G) protein, and the Small Hydrophobic (SH) protein (Schildgen et al., 2011). The F protein is essential for viral entry and is the primary target for neutralizing antibodies, whereas the G protein facilitates initial cell surface binding but lacks the neuraminidase and hemagglutinating activities typical of HN proteins (Bi et al., 2007). Consequently, the Human metapneumovirus hemagglutinin-neuraminidase protein is a biologically non-existent entity for this virus, and therapeutic development for hMPV focuses on the F protein rather than an HN-like target.
Not applicable; this protein is not encoded by the Human metapneumovirus genome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human metapneumovirus hemagglutinin-neuraminidase protein (hMPV HN).